NextCell Pharma
1.81
SEK
+0.56 %
NXTCL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+0.56%
+3.43%
+43.65%
+27.46%
-12.87%
-22.32%
-70.99%
-43.49%
-18.15%
www.nextcellpharma.com/investerare
NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.
Revenue
10.66M
EBIT %
-404.97 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NXTCL
Daily low / high price
1.71 / 1.82
SEK
Market cap
132.3M SEK
Turnover
384.57K SEK
Volume
219K
Financial calendar
Interim report
2025-01-30
Interim report
2025-04-25
Interim report
2025-07-24
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 15.6 % | 15.6 % |
| Diamyd Medical AB | 7.2 % | 7.2 % |
| Ålandsbanken | 3.9 % | 3.9 % |
| Nordnet Pensionsförsäkring | 3.3 % | 3.3 % |
| Pabros AB | 2.4 % | 2.4 % |
| Martin Larsen | 2.2 % | 2.2 % |
| Anders Essen-Möller | 2.2 % | 2.2 % |
| Nordea Livförsäkring Sverige AB | 1.7 % | 1.7 % |
| Clearstream Banking | 1.6 % | 1.6 % |
| Filip Wirefors | 1.5 % | 1.5 % |
ShowingAll content types
Valberedningen i NextCell Pharma AB föreslår Eva Sjökvist Saers som ny styrelseledamot
NextCell Pharma AB: QVances partnerskap driver innovation inom avancerade terapier
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools